Mglu5 receptor functional interactions and addiction

Frontiers in Pharmacology

Volumn 3 MAY, Issue , 2012, Pages

  Brown, Robyn M ^a   Mustafa, Sanam ^b   Ayoub, Mohammed Akli ^b   Dodd, Peter R ^c   Pfleger, Kevin D G ^b,d,e   Lawrence, Andrew J ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d Dimerix Bioscience Pty Ltd   (Australia)

^e PATHWEST LABORATORY MEDICINE   (Australia)

Author keywords

Drug addiction; Drug seeking; Heteromer; Hub receptor; Metabotropic glutamate receptor; Metabotropic glutamate receptor type 5; Receptor interaction

Indexed keywords

3 [(2-METHYL 1,3 THIAZOL 4 YL)ETHYNYL]PYRIDINE; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE D2 RECEPTOR; ADENOSINE RECEPTOR; ALCOHOL; COCAINE; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; G PROTEIN COUPLED RECEPTOR; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR ANTAGONIST; METHAMPHETAMINE; MORPHINE; NICOTINE; OPIATE; PHENCYCLIDINE; QUINPIROLE; UNCLASSIFIED DRUG;

ALCOHOLISM; ARTICLE; BRAIN FUNCTION; DRUG DEPENDENCE; DRUG POTENTIATION; DRUG SEEKING BEHAVIOR; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; SIGNAL TRANSDUCTION;

EID: 84866018986     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00084     Document Type: Article

References (109)

1. Adams, C. L., Cowen, M. S., Short, J. L., and Lawrence, A. J. (2008). Combined antagonism of glutamate mGlu5 and adenosine A2A receptors interact to regulate alcohol-seeking in rats. Int. J. Neuropsychopharmacol. 11, 229-241.
2. Adams, C. L., Short, J. L., and Lawrence, A. J. (2010). Cue-conditioned alcohol seeking in rats following abstinence: involvement of mGlu5 receptors. Br. J. Pharmacol. 159, 534-542.
3. Agnati, L. F., Ferre, S., Lluis, C., Franco, R., and Fuxe, K. (2003). Molecular mechanisms and therapeutical implications of intramembrane receptor/receptor interactions among heptahelical receptors with examples from the striatopallidal GABA neurons. Pharmacol. Rev. 55, 509-550.
4. Agnati, L. F., Fuxe, K., Woods, A. S., Genedani, S., and Guidolin, D. (2009). Theoretical considerations on the topological organization of receptor mosaics. Curr. Protein Pept. Sci. 10, 559-569.
5. Agnati, L. F., Fuxe, K., Zoli, M., Rondanini, C., and Ogren, S. O. (1982). New vistas on synaptic plasticity: the receptor mosaic hypothesis of the engram. Med. Biol. 60, 183-190.
6. Agnati, L. F., Guidolin, D., Albertin, G., Trivello, E., Ciruela, F., Genedani, S., Tarakanov, A., and Fuxe, K. (2010a). An integrated view on the role of receptor mosaics at perisynaptic level: focus on adenosine A(2A),dopamine D(2),cannabinoid CB(1), and metabotropic glutamate mGlu(5) receptors. J. Recept. Signal Transduct. Res. 30, 355-369.
7. Agnati, L. F., Guidolin, D., Vilardaga, J. P., Ciruela, F., and Fuxe, K. (2010b). On the expanding terminology in the GPCR field: the meaning of receptor mosaics and receptor heteromers. J. Recept. Signal Transduct. Res. 30, 287-303.
8. Albizu, L., Moreno, J. L., Gonzalez-Maeso, J., and Sealfon, S. C. (2010). Heteromerization of G proteincoupled receptors: relevance to neurological disorders and neurotherapeutics. CNS Neurol. Disord. Drug Targets 9, 636-650.
9. Arolfo, M. P.,Yao, L., Gordon, A. S., Diamond, I., and Janak, P. H. (2004). Ethanol operant self-administration in rats is regulated by adenosine A2 receptors. Alcohol. Clin. Exp. Res. 28, 1308-1316.
10. Attucci, S., Carla,V., Mannaioni, G., and Moroni, F. (2001). Activation of type 5 metabotropic glutamate receptors enhances NMDA responses in mice cortical wedges. Br. J. Pharmacol. 132, 799-806.
11. Backstrom, P., Bachteler, D., Koch, S., Hyytia, P., and Spanagel, R. (2004). mGluR5 antagonist MPEP reduces ethanol-seeking and relapse behavior. Neuropsychopharmacology 29, 921-928.
12. Backstrom, P., and Hyytia, P. (2006). Ionotropic and metabotropic glutamate receptor antagonism attenuates cue-induced cocaine seeking. Neuropsychopharmacology 31, 778-786.
13. Bespalov, A. Y., Dravolina, O. A., Sukhanov, I., Zakharova, E., Blokhina, E., Zvartau, E., Danysz, W., Van Heeke, G., and Markou, A. (2005). Metabotropic glutamate receptor (mGluR5) antagonist MPEP attenuated cueand schedule-induced reinstatement of nicotine self-administration behavior in rats. Neuropharmacology 49(SUPPL. 1), 167-178.
14. Bird, M. K., Kirchhoff, J., Djouma, E., and Lawrence, A. J. (2008). Metabotropic glutamate 5 receptors regulate sensitivity to ethanol in mice. Int. J. Neuropsychopharmacol. 11, 765-774.
15. Bird, M. K., and Lawrence, A. J. (2009a). Group I metabotropic glutamate receptors: involvement in drugseeking and drug-induced plasticity. Curr. Mol. Pharmacol. 2, 83-94.
16. Bird, M. K., and Lawrence,A. J. (2009b). The promiscuous mGlu5 receptor-a range of partners for therapeutic possibilities? Trends Pharmacol. Sci. 30, 617-623.
17. Bird, M. K., Reid, C. A., Chen, F., Tan, H. O., Petrou, S., and Lawrence, A. J. (2010). Cocaine-mediated synaptic potentiation is absent in VTA neurons from mGlu5-deficient mice. Int. J. Neuropsychopharmacol. 13, 133-141.
18. Bonci, A., and Hopf, F. W. (2005). The dopamine D2 receptor: new surprises from an old friend. Neuron 47, 335-338.
19. Brown, R. M., Duncan, J. R., Stagnitti, M. R., Ledent, C., and Lawrence, A. J. (2011a). mGlu5 and adenosine A2A receptor interactions regulate the conditioned effects of cocaine. Int. J. Neuropsychopharmacol. 1-7. doi:10.1017/S146114571100126X. [Epub ahead of print].
20. Brown, R. M., Stagnitti, M. R., Duncan, J. R., and Lawrence, A. J. (2011b). The mGlu5 receptor antagonist MTEP attenuates opiate self-administration and cue-induced opiate-seeking behaviour in mice. Drug Alcohol Depend. doi:10.1016/j.drugalcdep.2011.11.002. [Epub ahead of print].
21. Brown, R. M., and Short, J. L. (2008). Adenosine A2A receptors and their role in drug addiction. J. Pharm. Pharmacol. 60, 1409-1430.
22. Brown, R. M., Short, J. L., Cowen, M. S., Ledent, C., and Lawrence, A. J. (2009). A differential role for the adenosine A2A receptor in opiate reinforcement vs opiate-seeking behavior. Neuropsychopharmacology 34, 844-856.
23. Cabello, N., Gandia, J., Bertarelli, D. C., Watanabe, M., Lluis, C., Franco, R., Ferre, S., Lujan, R., and Ciruela, F. (2009). Metabotropic glutamate type 5, dopamine D2 and adenosine A2A receptors form higher-order oligomers in living cells. J. Neurochem. 109, 1497-1507.
24. Canals, M., Marcellino, D., Fanelli, F., Ciruela, F., De Benedetti, P., Goldberg, S. R., Neve, K., Fuxe, K.,Agnati, L. F., Woods, A. S., Ferre, S., Lluis, C., Bouvier, M., and Franco, R. (2003). Adenosine A2A-dopamine D2 receptor-receptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J. Biol. Chem. 278, 46741-46749.
25. Chiamulera, C., Epping-Jordan, M. P., Zocchi, A., Marcon, C., Cottiny, C., Tacconi, S., Corsi, M., Orzi, F., and Conquet, F. (2001). Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice. Nat. Neurosci. 4, 873-874.
26. Ciruela, F., Casado, V., Rodrigues, R. J., Lujan, R., Burgueno, J., Canals, M., Borycz, J., Rebola, N., Goldberg, S. R., Mallol, J., Cortes, A., Canela, E. I., Lopez-Gimenez, J. F., Milligan, G., Lluis, C., Cunha, R. A., Ferre, S., and Franco, R. (2006). Presynaptic control of striatal glutamatergic neurotransmission by adenosine A1-A2A receptor heteromers. J. Neurosci. 26, 2080-2087.
27. Cleva, R. M., Hicks, M. P., Gass, J. T., Wischerath, K. C., Plasters, E. T., Widholm, J. J., and Olive, M. F. (2011). mGluR5 positive allosteric modulation enhances extinction learning following cocaine selfadministration. Behav. Neurosci. 125, 10-19.
28. Cleva, R. M., and Olive, M. F. (2011). Positive allosteric modulators of type 5 metabotropic glutamate receptors (mGluR5) and their therapeutic potential for the treatment of CNS disorders. Molecules 16, 2097-2106.
29. Coccurello, R., Breysse, N., and Amalric, M. (2004). Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats. Neuropsychopharmacology 29, 1451-1461.
30. Collins, D. J., and Lapsley, H. M. (2002). Counting the Cost: Estimates of the Social Costs of Drug Abuse in Australia in 1998-9. Canberra: Commonwealth Department of Health and Aged Care.
31. Cowen, M. S., Djouma, E., and Lawrence, A. J. (2005). The metabotropic glutamate 5 receptor antagonist 3-[(2-methyl-1,3thiazol-4-yl)ethynyl]-pyridine reduces ethanol self-administration in multiple strains of alcoholpreferring rats and regulates olfactory glutamatergic systems. J. Pharmacol. Exp. Ther. 315, 590-600.
32. Cowen, M. S., Krstew, E., and Lawrence, A. J. (2007). Assessing appetitive and consummatory phases of ethanol self-administration in C57BL/6J mice under operant conditions: regulation by mGlu5 receptor antagonism. Psychopharmacology (Berl.) 190, 21-29.
33. D'Alcantara, P., Ledent, C., Swillens, S., and Schiffmann, S. N. (2001). Inactivation of adenosine A2A receptor impairs long term potentiation in the accumbens nucleus without altering basal synaptic transmission. Neuroscience 107, 455-464.
34. Dalrymple, M. B., Pfleger, K. D., and Eidne, K. A. (2008). G proteincoupled receptor dimers: functional consequences, disease states and drug targets. Pharmacol. Ther. 118, 359-371.
35. Dejong, W. (1994). Relapse prevention: an emerging technology for promoting long-term drug abstinence. Int. J. Addict. 29, 681-705.
36. Dhami, G. K., and Ferguson, S. S. (2006). Regulation of metabotropic glutamate receptor signaling, desensitization and endocytosis. Pharmacol. Ther. 111, 260-271.
37. Diaz-Cabiale, Z., Vivo, M., Del Arco, A., O'Connor, W. T., Harte, M. K., Muller, C. E., Martinez, E., Popoli, P., Fuxe, K., and Ferre, S. (2002). Metabotropic glutamate mGlu5 receptor-mediated modulation of the ventral striopallidal GABA pathway in rats. Interactions with adenosine A(2A) and dopamine D(2) receptors. Neurosci. Lett. 324, 154-158.
38. Fastbom, J., Pazos, A., and Palacios, J. M. (1987). The distribution of adenosine A1 receptors and 5′nucleotidase in the brain of some commonly used experimental animals. Neuroscience 22, 813-826.
39. Ferre, S., Agnati, L. F., Ciruela, F., Lluis, C., Woods, A. S., Fuxe, K., and Franco, R. (2007a). Neurotransmitter receptor heteromers and their integrative role in "local modules": the striatal spine module. Brain Res. Rev. 55, 55-67.
40. Ferre, S., Ciruela, F., Woods, A. S., Lluis, C., and Franco, R. (2007b). Functional relevance of neurotransmitter receptor heteromers in the central nervous system. Trends Neurosci. 30, 440-446.
41. Ferre, S., Diamond, I., Goldberg, S. R., Yao, L., Hourani, S. M., Huang, Z. L., Urade, Y., and Kitchen, I. (2007c). Adenosine A2A receptors in ventral striatum, hypothalamus and nociceptive circuitry implications for drug addiction, sleep and pain. Prog. Neurobiol. 83, 332-347.
42. Ferre, S., Baler, R., Bouvier, M., Caron, M. G., Devi, L. A., Durroux, T., Fuxe, K., George, S. R., Javitch, J. A., Lohse, M. J., Mackie, K., Milligan, G., Pfleger, K. D., Pin, J. P., Volkow, N. D.,Waldhoer, M.,Woods, A. S., and Franco, R. (2009). Building a new conceptual framework for receptor heteromers. Nat. Chem. Biol. 5, 131-134.
43. Ferre, S., Ciruela, F., Canals, M., Marcellino, D., Burgueno, J., Casado, V., Hillion, J., Torvinen, M., Fanelli, F., Benedetti Pd, P., Goldberg, S. R., Bouvier, M., Fuxe, K., Agnati, L. F., Lluis, C., Franco, R., and Woods, A. (2004). Adenosine A2A-dopamine D2 receptor-receptor heteromers. Targets for neuro-psychiatric disorders. Parkinsonism Relat. Disord. 10, 265-271.
44. Ferre, S., Karcz-Kubicha, M., Hope, B. T., Popoli, P., Burgueno, J., Gutierrez, M. A., Casado, V., Fuxe, K., Goldberg, S. R., Lluis, C., Franco, R., and Ciruela, F. (2002). Synergistic interaction between adenosine A2A and glutamate mGlu5 receptors: implications for striatal neuronal function. Proc. Natl. Acad. Sci. U.S.A. 99, 11940-11945.
45. Ferre, S., O'Connor, W. T., Snaprud, P., Ungerstedt, U., and Fuxe, K. (1994). Antagonistic interaction between adenosine A2A receptors and dopamine D2 receptors in the ventral striopallidal system. Implications for the treatment of schizophrenia. Neuroscience 63, 765-773.
46. Ferre, S., Popoli, P., Rimondini, R., Reggio, R., Kehr, J., and Fuxe, K. (1999). Adenosine A2A and group I metabotropic glutamate receptors synergistically modulate the binding characteristics of dopamine D2 receptors in the rat striatum. Neuropharmacology 38, 129-140.
47. Fink, J. S., Weaver, D. R., Rivkees, S. A., Peterfreund, R. A., Pollack, A. E., Adler, E. M., and Reppert, S. M. (1992). Molecular cloning of the rat A2 adenosine receptor: selective coexpression with D2 dopamine receptors in rat striatum. Mol. Brain Res. 14, 186-195.
48. Fontinha, B. M., Delgado-Garcis, J. M., Madronal, N., Ribeiro, J. A., Sebastiao, A. M., and Gruart, A. (2009). Adenosine A2A receptor modulation of hippocampal CA3-CA1 synapse plasticity during associative learning in behaving mice. Neuropsychopharmacology 34, 1865-1874.
49. Fredholm, B. B., Abbracchio, M. P., Burnstock, G., Daly, J. W., Harden, T. K., Jacobson, K. A., Leff, P., and Williams, M. (1994). VI. Nomenclature and classification of purinoceptors. Pharmacol. Rev. 46, 143-156.
50. Fredholm, B. B., Ap, I. J., Jacobson, K. A., Klotz, K. N., and Linden, J. (2001a). International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 53, 527-552.
51. Fredholm, B. B., Irenius, E., Kull, B., and Schulte, G. (2001b). Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem. Pharmacol. 61, 443-448.
52. Fredholm, B. B., and Svenningsson, P. (2003). Adenosine-dopamine interactions: development of a concept and some comments on therapeutic possibilities. Neurology 61, S5-S9.
53. Fuxe, K., Agnati, L. F., Jacobsen, K., Hillion, J., Canals, M., Torvinen, M., Tinner-Staines, B., Staines, W., Rosin, D., Terasmaa, A., Popoli, P., Leo, G., Vergoni, V., Lluis, C., Ciruela, F., Franco, R., and Ferre, S. (2003). Receptor heteromerization in adenosine A2A receptor signaling: relevance for striatal function and Parkinson's disease. Neurology 61, S19-S23.
54. Fuxe, K., Canals, M., Torvinen, M., Marcellino, D., Terasmaa, A., Genedani, S., Leo, G., Guidolin, D., Diaz-Cabiale, Z., Rivera, A., Lundstrom, L., Langel, U., Narvaez, J., Tanganelli, S., Lluis, C., Ferre, S., Woods, A., Franco, R., and Agnati, L. F. (2007). Intramembrane receptorreceptor interactions: a novel principle in molecular medicine. J. Neural Transm. 114, 49-75.
55. Fuxe, K., and Kenakin, T. (2010). The changing world of G proteincoupled receptors. J. Recept. Signal Transduct. Res. 30, 271.
56. Fuxe, K., Marcellino, D., Borroto-Escuela, D. O., Guescini, M., Fernandez-Duenas, V., Tanganelli, S., Rivera, A., Ciruela, F., and Agnati, L. F. (2010). Adenosine-dopamine interactions in the pathophysiology and treatment of CNS disorders. CNS Neurosci. Ther. 16, e18-e42.
57. Fuxe, K., Marcellino, D., Rivera, A., Diaz-Cabiale, Z., Filip, M., Gago, B., Roberts, D. C., Langel, U., Genedani, S., Ferraro, L., De La Calle, A., Narvaez, J., Tanganelli, S., Woods, A., and Agnati, L. F. (2008). Receptorreceptor interactions within receptor mosaics. Impact on neuropsychopharmacology. Brain Res. Rev. 58, 415-452.
58. Gass, J. T., and Olive, M. F. (2009). Positive allosteric modulation of mGluR5 receptors facilitates extinction of a cocaine contextual memory. Biol. Psychiatry 65, 717-720.
59. Gass, J. T., Osborne, M. P., Watson, N. L., Brown, J. L., and Olive, M. F. (2009). mGluR5 antagonism attenuates methamphetamine reinforcement and prevents reinstatement of methamphetamine-seeking behavior in rats. Neuropsychopharmacology 34, 820-833.
60. Gerfen, C. R. (1992). The neostriatal mosaic: multiple levels of compartmental organization. Trends Neurosci. 15, 133-139.
61. Gimenez-Llort, L., Schiffmann, S. N., Shmidt, T., Canela, L., Camon, L., Wassholm, M., Canals, M., Terasmaa, A., Fernandez-Teruel, A., Tobena, A., Popova, E., Ferre, S., Agnati, L., Ciruela, F., Martinez, E., Scheel-Kruger, J., Lluis, C., Franco, R., Fuxe, K., and Bader, M. (2007). Working memory deficits in transgenic rats overexpressing human adenosine A2A receptors in the brain. Neurobiol. Learn. Mem. 87, 42-56.
62. Gossop, M., Green, L., Phillips, G., and Bradley,B. (1989). Lapse,relapse and survival among opiate addicts after treatment. A prospective follow-up study. Br. J. Psychiatry 154, 348-353.
63. Hettinger, B. D., Lee, A., Linden, J., and Rosin, D. L. (2001). Ultrastructural localization of adenosine A2A receptors suggests multiple cellular sites for modulation of GABAergic neurons in rat striatum. J. Comp. Neurol. 431, 331-346.
64. Jupp,B.,and Lawrence,A. J. (2009). New horizons for therapeutics in drug and alcohol abuse. Pharmacol. Ther. 125, 138-168.
65. Kachroo, A., Orlando, L. R., Grandy, D. K., Chen, J. F., Young, A. B., and Schwarzschild, M. A. (2005). Interactions between metabotropic glutamate 5 and adenosine A(2A) receptors in normal and parkinsonian mice. J. Neurosci. 25, 10414-10419.
66. Kalivas, P. W. (2009). The glutamate homeostasis hypothesis of addiction. Nat. Rev. Neurosci. 10,561-572.
67. Kalivas, P. W., and McFarland, K. (2003). Brain circuitry and the reinstatement of cocaine-seeking behavior. Psychopharmacology (Berl.) 168, 44-56.
68. Kalivas, P. W., Volkow, N., and Seamans, J. (2005). Unmanageable motivation in addiction: a pathology in prefrontal-accumbens glutamate transmission. Neuron 45, 647-650.
69. Kennedy, M. B. (2000). Signalprocessing machines at the postsynaptic density. Science 290, 750-754.
70. Kenny, P. J., Paterson, N. E., Boutrel, B., Semenova, S., Harrison, A. A., Gasparini, F., Koob, G. F., Skoubis, P. D., and Markou, A. (2003). Metabotropic glutamate 5 receptor antagonist MPEP decreased nicotine and cocaine self-administration but not nicotine and cocaine-induced facilitation of brain reward function in rats. Ann. N. Y. Acad. Sci. 1003, 415-418.
71. Keywood, C., Wakefield, M., and Tack, J. (2009). A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease. Gut 58, 1192-1199.
72. Kreitzer, A. C., and Malenka, R. C. (2008). Striatal plasticity and basal ganglia circuit function. Neuron 60, 543-554.
73. Le Moine, C., and Bloch, B. (1995). D1 and D2 dopamine receptor gene expression in the rat striatum: sensitive cRNA probes demonstrate prominent segregation of D1 and D2 mRNAs in distinct neuronal populations of the dorsal and ventral striatum. J. Comp. Neurol. 355, 418-426.
74. Lindemann, L., Jaeschke, G., Michalon, A., Vieira, E., Honer, M., Spooren, W., Porter, R., Hartung, T., Kolczewski, S., Buttelmann, B., Flament, C., Diener, C., Fischer, C., Gatti, S., Prinssen, E. P., Parrott, N., Hoffmann, G., and Wettstein, J. G. (2011). CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor. J. Pharmacol. Exp. Ther. 339, 474-486.
75. Lindsley, C. W., Wisnoski, D. D., Leister, W. H., O'brien J, A., Lemaire, W., Williams, D. L. Jr., Burno, M., Sur, C., Kinney, G. G., Pettibone, D. J., Tiller, P. R., Smith, S., Duggan, M. E., Hartman, G. D., Conn, P. J., and Huff, J. R. (2004). Discovery of positive allosteric modulators for the metabotropic glutamatereceptorsubtype5fromaseries of N-(1,3-diphenyl-1Hpyrazol-5yl)benzamides that potentiate receptor function in vivo. J. Med. Chem. 47, 5825-5828.
76. Liu, F., Grauer, S., Kelley, C., Navarra, R., Graf, R., Zhang, G., Atkinson, P. J., Popiolek, M., Wantuch, C., Khawaja, X., Smith, D., Olsen, M., Kouranova, E., Lai, M., Pruthi, F., Pulicicchio, C., Day, M., Gilbert, A., Pausch, M. H., Brandon, N. J., Beyer, C. E., Comery, T. A., Logue, S., Rosenzweig-Lipson, S., and Marquis, K. L. (2008). ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piper idin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. J. Pharmacol. Exp. Ther. 327, 827-839.
77. Lu, Y. M., Jia, Z., Janus, C., Henderson, J. T., Gerlai, R.,Wojtowicz, J. M., and Roder, J. C. (1997). Mice lacking metabotropic glutamate receptor 5 show impaired learning and reduced CA1 long-term potentiation (LTP) but normal CA3 LTP. J. Neurosci. 17, 5196-5205.
78. Missale, C., Nash, S. R., Robinson, S. W., Jaber, M., and Caron, M. G. (1998). Dopamine receptors: from structure to function. Physiol. Rev. 78, 189-225.
79. Mustafa, S., Ayoub, M. A., and Pfleger, K. D. G. (2010). Uncovering GPCR heteromer-biased ligands. Drug Discov. Today Technol. 7, e77-e85.
80. Naisbitt, S., Kim, E., Tu, J. C., Xiao, B., Sala, C., Valtschanoff, J., Weinberg, R. J., Worley, P. F., and Sheng, M. (1999). Shank, a novel family of postsynaptic density proteins that binds to the NMDA receptor/PSD95/GKAP complex and cortactin. Neuron 23, 569-582.
81. Nishi, A., Liu, F., Matsuyama, S., Hamada, M., Higashi, H., Nairn, A. C., and Greengard, P. (2003). Metabotropic mGlu5 receptors regulate adenosine A2A receptor signaling. Proc. Natl. Acad. Sci. U.S.A. 100, 1322-1327.
82. Novak, M., Halbout, B., O'Connor, E. C., Rodriguez Parkitna, J., Su, T., Chai, M., Crombag, H. S., Bilbao, A., Spanagel,R.,Stephens,D. N.,Schutz, G., and Engblom, D. (2010). Incentive learning underlying cocaineseeking requires mGluR5 receptors located on dopamine D1 receptorexpressing neurons. J. Neurosci. 30, 11973-11982.
83. O'Connor, E. C., Crombag, H. S., Mead, A. N., and Stephens, D. N. (2010). The mGluR5 antagonist MTEP dissociates the acquisition of predictive and incentive motivational properties of reward-paired stimuli in mice. Neuropsychopharmacology 35, 1807-1817.
84. Olive, M. F. (2009). Metabotropic glutamate receptor ligands as potential therapeutics for addiction. Curr. Drug Abuse Rev. 2, 83-98.
85. Popoli, P., Pezzola, A., Torvinen, M., Reggio, R., Pintor, A., Scarchilli, L., Fuxe, K., and Ferre, S. (2001). The selective mGlu5 receptor agonist CHPG inhibits quinpirole-induced turning in 6-hydroxydopaminelesioned rats and modulates the binding characteristics of dopamine D2 receptors in the rat striatum: interactions with adenosine A2A receptors. Neuropsychopharmacology 25, 505-513.
86. Quiroz, C., Lujan, R., Uchigashima, M., Simoes, A. P., Lerner, T. N., Borycz, J., Kachroo, A., Canas, P. M., Orru, M., Schwarzschild, M. A., Rosin, D. L., Kreitzer, A. C., Cunha, R. A., Watanabe, M., and Ferre, S. (2009). Key modulatory role of presynaptic adenosine A2A receptors in cortical neurotransmission to the striatal direct pathway. ScientificWorldJournal 9, 1321-1344.
87. Reichel, C. M., Schwendt, M., Mcginty, J. F., Olive, M. F., and See, R. E. (2011). Loss of object recognition memory produced by extended access to methamphetamine self-administration is reversed by positive allosteric modulation of metabotropic glutamate receptor 5. Neuropsychopharmacology 36, 782-792.
88. Robbins, T. W., Ersche, K. D., and Everitt, B. J. (2008). Drug addiction and the memory systems of the brain. Ann. N. Y. Acad. Sci. 1141, 1-21.
89. Rodrigues, R. J., Alfaro, T. M., Rebola, N., Oliveira, C. R., and Cunha, R. A. (2005). Co-localization and functional interaction between adenosine A2A and metabotropic group 5 receptors in glutamatergic nerve terminals of the rat striatum. J. Neurochem. 92, 433-441.
90. Romano, C., Sesma, M. A., Mcdonald, C. T., O'malley, K., Van Den Pol, A. N., and Olney, J. W. (1995). Distribution of metabotropic glutamate receptor mGluR5 immunoreactivity in rat brain. J. Comp. Neurol. 355, 455-469.
91. Rosin, D. L., Hettinger, B. D., Lee, A., and Linden, J. (2003). Anatomy of adenosine A2A receptors in brain: morphological substrates for integration of striatal function. Neurology 61, S12-S18.
92. Schiffmann, S. N., Fisone, G., Moresco, R.,Cunha,R. A.,and Ferre,S. (2007). Adenosine A2A receptors and basal ganglia physiology. Prog. Neurobiol. 83, 277-292.
93. Sesack, S. R., and Pickel, V. M. (1992). Prefrontal cortical efferents in the rat synapse on unlabeled neuronal targets of catecholamine terminals in the nucleus accumbens septi and on dopamine neurons in the ventral tegmental area. J. Comp. Neurol. 320, 145-160.
94. Shigemoto, R., Nomura, S., Ohishi, H., Sugihara, H., Nakanishi, S., and Mizuno, N. (1993). Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain. Neurosci. Lett. 163, 53-57.
95. Simonyi, A., Schachtman, T. R., and Christoffersen, G. R. (2005). The role of metabotropic glutamate receptor 5 in learning and memory processes. Drug News Perspect. 18, 353-361.
96. Smith, A. D., and Bolam, J. P. (1990). The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones. Trends Neurosci. 13, 259-265.
97. Smith, Y., Charara, A., Hanson, J. E., Paquet, M., and Levey, A. I. (2000). GABA(B) and group I metabotropic glutamate receptors in the striatopallidal complex in primates. J. Anat. 196(Pt 4), 555-576.
98. Sung, K. W., Choi, S., and Lovinger, D. M. (2001). Activation of group I mGluRs is necessary for induction of long-term depression at striatal synapses. J. Neurophysiol. 86, 2405-2412.
99. Svenningsson, P., Le Moine, C., Kull, B., Sunahara, R., Bloch, B., and Fredholm, B. B. (1997). Cellular expression of adenosine A2A receptor messenger RNA in the rat central nervous system with special reference to dopamine innervated areas. Neuroscience 80, 1171-1185.
100. Tallaksen-Greene, S. J., Kaatz, K. W., Romano, C., and Albin, R. L. (1998). Localization of mGluR1alike immunoreactivity and mGluR5like immunoreactivity in identified populations of striatal neurons. Brain Res. 780, 210-217.
101. Tatarczynska, E., Klodzinska, A., Chojnacka-Wojcik, E., Palucha, A., Gasparini, F., Kuhn, R., and Pilc, A. (2001). Potential anxiolyticand antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist. Br. J. Pharmacol. 132, 1423-1430.
102. Tebano, M. T., Martire, A., Rebola, N., Pepponi, R., Domenici, M. R., Gro, M. C., Schwarzschild, M. A., Chen, J. F., Cunha, R. A., and Popoli, P. (2005). Adenosine A2A receptors and metabotropic glutamate 5 receptors are co-localized and functionally interact in the hippocampus: a possible key mechanism in the modulation of N-methyl-Daspartate effects. J. Neurochem. 95, 1188-1200.
103. Testa, C. M., Standaert, D. G., Landwehrmeyer, G. B., Penney, J. B. Jr., and Young, A. B. (1995). Differential expression of mGluR5 metabotropic glutamate receptor mRNA by rat striatal neurons. J. Comp. Neurol. 354, 241-252.
104. Torvinen, M., Kozell, L. B., Neve, K. A., Agnati, L. F., and Fuxe, K. (2004). Biochemical identification of the dopamine D2 receptor domains interacting with the adenosine A2A receptor. J. Mol. Neurosci. 24, 173-180.
105. Totterdell, S., and Smith, A. D. (1989). Convergence of hippocampal and dopaminergic input onto identified neurons in the nucleus accumbens of the rat. J. Chem. Neuroanat. 2, 285-298.
106. Traynor, J. (2010). Regulator of G protein-signaling proteins and addictive drugs. Ann. N. Y. Acad. Sci. 1187, 341-352.
107. Vilardaga, J. P., Nikolaev, V. O., Lorenz, K., Ferrandon, S., Zhuang, Z., and Lohse, M. J. (2008). Conformational cross-talk between alpha2Aadrenergic and mu-opioid receptors controls cell signaling. Nat. Chem. Biol. 4, 126-131.
108. Yao, L., Mcfarland, K., Fan, P., Jiang, Z., Ueda, T., and Diamond, I. (2006). Adenosine A2A blockade prevents synergy between m-opiate and cannabinoid CB1 receptors and eliminates heroinseeking behavior in addicted rats. Proc. Natl. Acad. Sci. U.S.A. 103, 7877-7882.
109. Zerbib, F., Keywood, C., and Strabach, G. (2010). Efficacy, tolerability and pharmacokinetics of a modified release formulation of ADX10059, a negative allosteric modulator of metabotropic glutamate receptor 5: an esophageal pHimpedance study in healthy subjects. Neurogastroenterol. Motil. 22, 859-865, e231.